Baker Bros. Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Baker Bros. Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11,340	Closed	-$425K	–	122
2016 Q4	$425K	Hold	11,340	–	–	﹤0.01%	122
2016 Q3	$769K	Hold	11,340	–	–	0.01%	118
2016 Q2	$629K	Hold	11,340	–	–	0.01%	122
2016 Q1	$712K	Hold	11,340	–	–	0.01%	122
2015 Q4	$1.07M	Hold	11,340	–	–	0.01%	118
2015 Q3	$911K	Hold	11,340	–	–	0.01%	120
2015 Q2	$1.36M	Hold	11,340	–	–	0.01%	114
2015 Q1	$1.18M	Sell	11,340 -260	-2%	-$26.3K	0.01%	118
2014 Q4	$1.13M	Hold	11,600	–	–	0.01%	111
2014 Q3	$906K	Hold	11,600	–	–	0.01%	99
2014 Q2	$733K	Hold	11,600	–	–	0.01%	101
2014 Q1	$779K	Buy	+11,600	New	+$898K	0.01%	102

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Baker Bros. Advisors's ALNY Position: Q1 2017 in Review

Baker Bros. Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2017, closing a stake of 11,340 shares — an estimated $425K sold.

Baker Bros. Advisors first reported a position in ALNY in Q1 2014 and held it in 12 quarters. The position peaked at $1.36M in Q2 2015. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

Baker Bros. Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Baker Bros. Advisors sold 11,340 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $425K.
Baker Bros. Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Baker Bros. Advisors's Alnylam Pharmaceuticals position peaked at $1.36M in Q2 2015.
199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.